Home/ Stocks/ ALNY

Alnylam Pharmaceuticals, Inc.

ALNY XNAS

$219.20 +2.83 (+1.31%) ▲ 15-min delayed

Open

$217.31

High

$219.64

Low

$210.49

Volume

1.74M

Market Cap

$28.92B

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 2.5K Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$1.29B	$164.49M	$1.23
FY 2025	$3.71B	$313.75M	$2.39
Q3 2025	$1.25B	$251.08M	$1.91
Q2 2025	$773.69M	$-66,277,000	$-0.51

TickerDaily Coverage

Why Is Vir Biotechnology, Inc. Common Stock (VIR) Stock Up 71.4% Today?

Market News Alex Chen · Feb 24, 2026

Vir Biotechnology (VIR) stock rocketed 71.4% to $7.43, posting one of the day's largest biotech...

View All Coverage →

Get ALNY Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Alnylam Pharmaceuticals, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.